| Autor: |
Bowers, J. T., Anna, J., Bair, S. M., Annunzio, K., Epperla, N., Pullukkara, J. Joy, Gaballa, S., Spinner, M., Li, S., Messmer, M., Nguyen, J., Ayers, E. C., Wagner, C. B., Hu, B., Di, M., Huntington, S. F., Furqan, F., Shah, N. N., Chen, C., Ballard, H. J. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p359-360, 2p |
| Abstrakt: |
In our cohort, which includes pts who would not have been eligible for the pivotal ECHELON-1 trial, BV discontinuation rates were higher than previously reported, but 2-year outcomes remain comparable; discontinuation of BV was not associated with inferior PFS. B Introduction: b BV in combination with doxorubicin, vinblastine, and dacarbazine (AVD) is the new standard of care for newly diagnosed stage III/IV cHL. Brentuximab vedotin (BV) + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): incidence and management of peripheral neuropathy (PN) in a multi-institution cohort. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text